Ibio (IBIO) AI Stock Analysis

• Market Cap: $60.72M
• Dividend Yield: N/A
• Average Volume (3M): 10.01M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.31
• Revenue Growth: 185.71%
• EPS Growth: 79.03%
• Country: US
• Employees: 16
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.11
• Shares Outstanding: 22,487,309
• 10 Day Avg. Volume: 3,169,908
• 30 Day Avg. Volume: 10,011,308
• PEG Ratio: <0.01
• Price to Book (P/B): 0.54
• Price to Sales (P/S): 20.03
• P/FCF Ratio: -0.52
• Enterprise Value/Market Cap: -0.04
• Enterprise Value/Revenue: -4.83
• Enterprise Value/Gross Profit: -11.45
• Enterprise Value/Ebitda: 0.13
• 1Y Price Target: $4.75
• Price Target Upside: 75.93% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 55 Neutral
• Price Target: $2.50 ▼(-7.41% Downside)

The score is held back primarily by weak financial performance (minimal revenue, large losses, and sustained cash burn). Offsetting this are improving/low leverage and supportive corporate developments (financing extending runway), alongside strong technical momentum with the stock trading above major moving averages.

Positive Factors

Proprietary plant-based FastPharming platform

A proprietary plant-based FastPharming platform is a durable competitive asset: it can lower manufacturing costs, shorten development timelines and attract partners/licensing deals. This supports recurring collaboration revenue and differentiation in biologics manufacturing over the medium term.

Promising preclinical data for IBIO-610 (extended half-life)

Preclinical IBIO-610 data showing a projected very long human half-life is a structural positive: if translated clinically it could create a differentiated product with infrequent dosing, higher adherence and commercial premium, materially enhancing the program's long-term value.

Low leverage and improved balance sheet position

Very low leverage gives the company financial flexibility to fund R&D or strategic partnerships without heavy interest burden. This reduces near-term default risk and supports the ability to raise capital on less dilutive terms, aiding execution over the coming months.

Negative Factors

Very small revenue scale

Sub-$1M trailing revenue indicates the business has not yet achieved commercial traction; fixed costs and R&D far outpace sales. Reliance on partnerships, grants or licensing rather than organic product revenue raises execution and scalability risk over the medium term.

Persistent cash burn and negative operating cash flow

Sustained negative operating and free cash flow means ongoing external financing is required to fund operations and trials. That creates dilution or covenant risk, constrains strategic choices, and can impair the company’s ability to advance programs without clear near-term funding sources.

Deep operating losses and negative ROE

Large operating losses and a negative ROE reflect failure so far to generate shareholder value and sustainable margins. Continued losses pressure equity, may limit reinvestment capacity, and increase dependency on external capital, elevating long-term execution and financing risk.

Ibio Business Overview & Revenue Model

Company Description

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

How the Company Makes Money

Ibio generates revenue through a combination of product sales, research and development collaborations, and licensing agreements. The company partners with other biotech firms and academic institutions to co-develop its products, sharing in the financial benefits of successful outcomes. Additionally, Ibio may receive upfront payments, milestone payments, and royalties from its partners based on the sales of products developed using its technology. The revenue model is further supported by grants and contracts, particularly for vaccine development and other projects that align with public health initiatives.

Ibio Financial Statement Overview

Summary

Ibio faces significant financial challenges, with persistent losses and negative cash flows. Despite a low debt-to-equity ratio, the company's inability to generate profits and positive cash flow raises concerns about its long-term sustainability.

Income Statement

Ibio's income statement reveals significant challenges with profitability. Despite a slight revenue growth of 6.67% in the latest year, the company has consistently reported negative net profit margins, with the most recent at -45.94%. The EBIT and EBITDA margins are also deeply negative, indicating operational inefficiencies. The gross profit margin remains positive, but the overall financial health is hindered by substantial losses.

Balance Sheet

The balance sheet shows a relatively low debt-to-equity ratio of 0.24, suggesting manageable leverage levels. However, the return on equity is negative, reflecting the company's inability to generate profits from shareholders' equity. The equity ratio indicates a moderate level of equity financing, but the persistent losses pose a risk to financial stability.

Cash Flow

Cash flow analysis highlights ongoing cash flow challenges. The operating cash flow to net income ratio is negative, indicating that the company is not generating sufficient cash from operations to cover its losses. Free cash flow growth is negative, and the free cash flow to net income ratio is slightly above 1, suggesting some alignment between cash flow and reported losses, but overall cash management remains a concern.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	500.00K	400.00K	225.00K	0.00	1.88M	2.37M
Gross Profit	211.00K	400.00K	225.00K	0.00	-1.91M	909.00K
EBITDA	-18.78M	-17.04M	-14.02M	-27.85M	-25.72M	-28.55M
Net Income	-20.11M	-18.38M	-24.91M	-65.01M	-50.39M	-23.21M
Balance Sheet
Total Assets	64.16M	23.18M	28.73M	41.21M	99.41M	146.97M
Cash, Cash Equivalents and Short-Term Investments	49.57M	8.58M	14.21M	7.33M	33.52M	96.97M
Total Debt	3.29M	3.51M	4.46M	17.07M	25.77M	32.72M
Total Liabilities	8.12M	8.30M	7.41M	25.83M	35.92M	38.40M
Stockholders Equity	56.04M	14.88M	21.32M	15.38M	63.48M	108.58M
Cash Flow
Free Cash Flow	-17.30M	-15.32M	-18.76M	-36.17M	-45.13M	-35.23M
Operating Cash Flow	-17.25M	-15.30M	-18.55M	-30.44M	-37.80M	-30.06M
Investing Cash Flow	-21.46M	742.00K	906.00K	7.01M	-5.13M	-26.48M
Financing Cash Flow	55.80M	8.93M	24.49M	2.30M	-5.80M	78.83M

Ibio Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.70
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IBIO, the sentiment is Positive. The current price of 2.7 is above the 20-day moving average (MA) of 2.03, above the 50-day MA of 1.65, and above the 200-day MA of 1.16, indicating a bullish trend. The MACD of 0.23 indicates Negative momentum. The RSI at 69.29 is Neutral, neither overbought nor oversold. The STOCH value of 81.87 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IBIO.

Ibio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IBIO	55 Neutral	$60.72M	-1.94	-54.50%	―	185.71%	79.03%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NERV	50 Neutral	$192.57M	-2.33	―	―	―	-323.61%
FBLG	44 Neutral	$22.48M	-0.80	-1292.87%	―	―	18.47%
PULM	43 Neutral	$8.62M	-1.38	-79.47%	―	-99.97%	35.59%
CMMB	39 Underperform	$11.02M	-0.98	-73.63%	―	―	53.19%

Ibio Corporate Events

iBio Announces Private Placement to Fund Pipeline Expansion

On January 8, 2026, iBio, Inc. entered into a securities purchase agreement with existing, healthcare-focused institutional investors for an at-the-market private placement of 1,408,481 common shares and pre-funded warrants to purchase up to 9,653,257 additional shares, at a price of $2.35 per share (or $2.349 per pre-funded warrant). The transaction, led by Frazier Life Sciences with Leerink Partners as lead placement agent and LifeSci Capital and Oppenheimer & Co. as co-placement agents, is expected to close on or about January 13, 2026 and generate approximately $26 million in gross proceeds. The funding is earmarked to advance iBio’s preclinical cardiometabolic pipeline, including IBIO-610, IBIO-600 and its myostatin and activin A bispecific programs, as well as other preclinical assets and general corporate purposes, and is expected to extend the company’s cash runway into calendar 2028; the deal also includes customary beneficial-ownership caps on warrant exercises and registration rights obligating iBio to register the resale of the newly issued securities.

The most recent analyst rating on (IBIO) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Ibio stock, see the IBIO Stock Forecast page.

iBio Confirms Directors and Auditor at Annual Meeting

On November 20, 2025, iBio, Inc. held its Annual Meeting of Stockholders where four proposals were voted on. The election of two Class II directors, Dr. Martin Brenner and Dr. Alexandra Kropotova, was confirmed for a three-year term. Stockholders ratified Grassi & Co. as the independent auditor for the fiscal year ending June 30, 2026. Additionally, stockholders approved executive compensation on an advisory basis and decided on a one-year frequency for future advisory votes on executive compensation, aligning with the Board’s recommendation.

The most recent analyst rating on (IBIO) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Ibio stock, see the IBIO Stock Forecast page.

iBio Regains Nasdaq Compliance with Bid Price Rule

On November 4, 2025, iBio, Inc. announced that it has regained compliance with the Nasdaq Listing Rule 5550(a)(2), which requires a minimum closing bid price of $1.00 per share. This follows a previous notification on July 29, 2025, indicating non-compliance due to the company’s stock price falling below the required threshold between June 13, 2025, and July 28, 2025. The issue is now resolved, closing the matter.

The most recent analyst rating on (IBIO) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Ibio stock, see the IBIO Stock Forecast page.

iBio Unveils Promising Preclinical Data for IBIO-610

On October 30, 2025, iBio, Inc. announced new preclinical data from its study on IBIO-610, an Activin E antibody candidate, showing an extended half-life of 33.2 days in obese non-human primates. This data, to be presented at ObesityWeek 2025, predicts a human half-life of up to 100 days, potentially allowing for twice-yearly dosing, which could significantly enhance patient experience and position IBIO-610 as a leading therapy for obesity and cardiometabolic diseases.

The most recent analyst rating on (IBIO) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Ibio stock, see the IBIO Stock Forecast page.